TY - JOUR
T1 - Single-cell transcriptomic analysis reveals reduction of cytotoxic NK cells in a subset of newly diagnosed multiple myeloma patients impacting outcome after daratumumab therapy
AU - Tahri, Sabrin
AU - de Jong, Madelon M.E.
AU - Fokkema, Cathelijne
AU - Papazian, Natalie
AU - Kellermayer, Zoltan
AU - Den Hollander, Chelsea
AU - Vermeulen, Michael
AU - van Duin, Mark
AU - van de Woestijne, Pieter
AU - Nasserinejad, Kazem
AU - Saraci, Elona
AU - D'Agostino, Mattia
AU - Gay, Francesca
AU - van der Velden, Vincent H.J.
AU - Zweegman, Sonja
AU - van de Donk, Niels W.C.J.
AU - Broijl, Annemiek
AU - Sonneveld, Pieter
AU - Cupedo, Tom
N1 - Copyright: © 2022 Elsevier Inc.
PY - 2022/8
Y1 - 2022/8
N2 - Here, we show that about 20% of NDMM patients have a relative reduction in cytotoxic NK cells, which was correlated with significantly shorter PFS following daratumumab-containing therapy in a frail cohort of NDMM patients. Our data suggest that defining BM NK cell composition could stratify patients and identify a subgroup less likely to benefit from therapies driven by NK cell-mediated ADCC.
AB - Here, we show that about 20% of NDMM patients have a relative reduction in cytotoxic NK cells, which was correlated with significantly shorter PFS following daratumumab-containing therapy in a frail cohort of NDMM patients. Our data suggest that defining BM NK cell composition could stratify patients and identify a subgroup less likely to benefit from therapies driven by NK cell-mediated ADCC.
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=eur_pure&SrcAuth=WosAPI&KeyUT=WOS:000895909200030&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.1016/S2152-2650(22)00302-0
DO - 10.1016/S2152-2650(22)00302-0
M3 - Meeting Abstract
SN - 2152-2650
VL - 22
SP - S17-S18
JO - Clinical Lymphoma Myeloma & Leukemia
JF - Clinical Lymphoma Myeloma & Leukemia
IS - Supplement
ER -